Compare Eli Lilly And Co (LLY) vs Raymond James Financial, Inc. (RJF) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Raymond James Financial (RJF) trades at $168.23, down slightly by 0.08% on the day. The stock shows a bullish technical trend with moving averages supporting upside momentum, while recent earnings beats and steady revenue growth highlight fundamental strength. Analyst consensus is positive with a $176.83 price target, and the company declared a $0.54 dividend payable in July 2026.

Outlook remains favorable given consistent earnings performance and strong analyst support, though rising expenses and market volatility pose risks. The stock's current valuation metrics, including a P/E of 15.9, suggest room for growth if execution continues. Key catalysts include upcoming Q2 2026 earnings and sustained advisor network expansion.